ICPerMed
INTERNATIONAL CONSORTIUM

Transfer of research results into the market: How to optimise a safe, fast and economic process to implement personalised medicine approaches?

Working Group III

Panel:

- Chair: **Prof. Anna Rita Franco Migliaccio** (University of Bologna, Italy)
- Vice-chair: **Dr. Sebastian Delbrück** (VDI/VDE Innovation + Technik GmbH, Germany)
- Rapporteur: **Prof. Dr. Jacques Demotes** (ECRIN, France)
- Vice-rapp.: **Ignacio Baanante** (National Health Institute Carlos III, ISCIII, Spain)

Leading questions:

- Technological challenges for Personalised Medicine research. Data generation and analysis.
- Methodological standards for Personalised Medicine studies.
- Which issues related to market and regulation have to be addressed first in order to facilitate market access of Personalised Medicine approaches?
- Entrepreneurial challenges common to all the previous questions.

Wrap up discussion points

- What is specific for PM vs. generic issues in the development of health products and IVD ?
  - Diagnostic / stratification ? Ex. new taxonomy
  - Treatments ? Ex. tissue-agnostic indication
- What should be the funding mechanisms / instruments for the various steps in PM development programmes ? (stratification, translatonal, clinical step)
- Beyond market access, what is the evidence required to foster adoption by HTA / insurance ?
- Industry missing in the discussion

Needs to address bottlenecks

- Need for early support to design the development plan
  - technology transfer
  - regulatory experts
  - ‘scientific advice’
  - HTA / payers
- Need for training and for new competencies (IP, data science, regulatory)
- Need for economic expertise, how will PM contain the cost of healthcare ?

Optimise the transfer of research results to market ?

- Training, support and expert advice
- Involment of HTA and health insurance
- Need to identify what are the industry expectations
- Need for venture capital investment